BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 37530808)

  • 1. Large Population Analysis of Secondary Cancers in Pediatric Leukemia Survivors.
    Yavvari S; Makena Y; Sukhavasi S; Makena MR
    Children (Basel); 2019 Nov; 6(12):. PubMed ID: 31795500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current knowledge and future research directions in treatment-related second primary malignancies.
    Morton LM; Swerdlow AJ; Schaapveld M; Ramadan S; Hodgson DC; Radford J; van Leeuwen FE
    EJC Suppl; 2014 Jun; 12(1):5-17. PubMed ID: 26217162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second malignant neoplasms within 5 years from first primary diagnosis in pediatric oncology patients in Canada: a population-based retrospective cohort study.
    Ricci C; Subburaj D; Lim K; Shukla N; Kaur J; Xie L; Laverty M; Zakaria D; Pole J; Pelland-Marcotte MC; Barber R; Israels SJ; Tran TH; Oberoi S; Renzi S; MacDonald T; Sung L; Kulkarni K
    Front Oncol; 2024; 14():1376652. PubMed ID: 38606094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testicular Cancer as a Model for Understanding the Impact of Evolving Treatment Strategies on the Long-Term Health of Cancer Survivors.
    Morton LM
    JNCI Cancer Spectr; 2020 Jun; 4(3):pkaa013. PubMed ID: 32455333
    [No Abstract]   [Full Text] [Related]  

  • 5. Correct to: Goal-Focused Emotion-Regulation Therapy (GET) in Young Adult Testicular Cancer Survivors: A Randomized Pilot Study.
    Ann Behav Med; 2024 Feb; 58(3):227. PubMed ID: 38141249
    [No Abstract]   [Full Text] [Related]  

  • 6. Back to the Future-Moving Forward for Testicular Cancer Survivors.
    Nichols CR; Nappi L; Kollmannsberger C; Hamilton R; Daneshmand S
    JNCI Cancer Spectr; 2020 Apr; 4(2):pkz082. PubMed ID: 32190816
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate-specific antigen concentrations.
    Ślusarczyk A; Baboudjian M; Zapała P; Yanagisawa T; Miszczyk M; Chlosta M; Krumpoeck P; Moschini M; Gandaglia G; Ploussard G; Rivas JG; Życzkowski M; Karakiewicz PI; Radziszewski P; Leapman MS; Shariat SF; Rajwa P
    Prostate; 2023 Nov; 83(15):1504-1515. PubMed ID: 37545342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of lncRNA/Pseudogene-miRNA Network Based on In Silico Approaches for Glycolysis Pathway to Identify Prostate Adenocarcinoma-Related Potential Biomarkers.
    Khorsand M; Mostafavi-Pour Z; Tahmasebi A; Omidvar Kordshouli S; Mousavi P
    Appl Biochem Biotechnol; 2024 Apr; 196(4):2332-2355. PubMed ID: 37542606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased circulating Th17 cell populations in patients with pancreatic ductal adenocarcinoma.
    Khan IA; Singh N; Gunjan D; Gopi S; Dash NR; Gupta S; Saraya A
    Immunogenetics; 2023 Oct; 75(5):433-443. PubMed ID: 37540314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence and Prognosis of Secondary Lung Cancer in Patients with Primary Nasal Cavity and Sinus Squamous Cell Carcinoma.
    Feng J; Jin G; Song X
    Adv Ther; 2022 Jun; 39(6):2533-2543. PubMed ID: 35357667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort.
    Meadows AT; Friedman DL; Neglia JP; Mertens AC; Donaldson SS; Stovall M; Hammond S; Yasui Y; Inskip PD
    J Clin Oncol; 2009 May; 27(14):2356-62. PubMed ID: 19255307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of risk factors and prediction models for secondary malignant neoplasms (SMNs)-free survival and SMNs-specific survival in testicular cancer survivors.
    Fu H; Talluri S; Rai S; Liang L; Trivedi J; Ankem MK
    World J Urol; 2023 Sep; 41(9):2413-2420. PubMed ID: 37530808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary malignant neoplasms in testicular cancer survivors.
    Curreri SA; Fung C; Beard CJ
    Urol Oncol; 2015 Sep; 33(9):392-8. PubMed ID: 26072728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era.
    Groot HJ; Lubberts S; de Wit R; Witjes JA; Kerst JM; de Jong IJ; Groenewegen G; van den Eertwegh AJM; Poortmans PM; Klümpen HJ; van den Berg HA; Smilde TJ; Vanneste BGL; Aarts MJ; Incrocci L; van den Bergh ACM; Jóźwiak K; van den Belt-Dusebout AW; Horenblas S; Gietema JA; van Leeuwen FE; Schaapveld M
    J Clin Oncol; 2018 Aug; 36(24):2504-2513. PubMed ID: 29989856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.
    van den Belt-Dusebout AW; de Wit R; Gietema JA; Horenblas S; Louwman MW; Ribot JG; Hoekstra HJ; Ouwens GM; Aleman BM; van Leeuwen FE
    J Clin Oncol; 2007 Oct; 25(28):4370-8. PubMed ID: 17906202
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.